We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Role of allo-SCT for CML in 2010.
- Authors
Venepalli, N.; Rezvani, K.; Mielke, S.; Savani, B. N.
- Abstract
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of CML. However, for a minority of patients who fail TKI or progress to advanced phase disease, allo-SCT remains the only therapeutic option. This review addresses the current indications for allo-SCT in CML and the role of conditioning (myeloablative vs reduced intensity), donor source (sibling vs volunteer unrelated donor), graft source (BM vs peripheral blood vs cord) and the value of pre-, peri- and post transplant use of TKI in the management of CML.
- Subjects
PROTEIN-tyrosine kinases; CHRONIC myeloid leukemia; PROTEIN-tyrosine kinase inhibitors; SENTENCE completion tests; AMINO acids
- Publication
Bone Marrow Transplantation, 2010, Vol 45, Issue 11, p1579
- ISSN
0268-3369
- Publication type
Article
- DOI
10.1038/bmt.2010.138